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Abstract
Background: The advent of rapid and inexpensive sequencing technology allows scientists to decipher
heterogeneity within primary tumours, between primary and metastatic sites, and between metastases. Charting
the evolutionary history of individual tumours has revealed drivers of tumour heterogeneity and highlighted its
impact on therapeutic outcomes.
Discussion: Scientists are using improved sequencing technologies to characterise and address the challenge of
tumour heterogeneity, which is a major cause of resistance to therapy and relapse. Heterogeneity may fuel
metastasis through the selection of rare, aggressive, somatically altered cells. However, extreme levels of
chromosomal instability, which contribute to intratumour heterogeneity, are associated with improved patient
outcomes, suggesting a delicate balance between high and low levels of genome instability.
Conclusions: We review evidence that intratumour heterogeneity influences tumour evolution, including
metastasis, drug resistance, and the immune response. We discuss the prevalence of tumour heterogeneity, and
how it can be initiated and sustained by external and internal forces. Understanding tumour evolution and
metastasis could yield novel therapies that leverage the immune system to control emerging tumour neo-antigens.
Keywords: Intratumour heterogeneity, Tumour progression, Metastasis, Linear evolution, Branched evolution,
Competitive evolution, Cooperative evolution, Mutation burden, Immunotherapy, Aneuploidy tolerance
Background
In his 1958 essay, Foulds [1] explains that linear tumour
progression, the orthodox view of tumour evolution at
the time, is the theory that neoplasia advances through
an orderly sequence from local invasion, to progressive
lymph node invasion, to metastasis [1]. Foulds goes on
to discuss tumour progression and metastasis in several
cancer types and concludes that neoplasia is not linear,
but a complex, ever-diverging route throughout tumour
development [1]. This was one of the first articulate
explanations of tumourigenesis as a multistep pathway
that can progress, persist, or regress [1]. Nowell’s 1976
[2] cancer evolution model proposed that genomic
instability drives branched evolutionary pathways from a
clone of origin. Heppner [3] reviewed literature on the
emergence of heterogeneity in tumours, and the
challenges surrounding its study, emphasising that
tumour cells exist in a society, and that the interactions
between heterogeneous populations are as important as
the subclones themselves [3].
Recent technological advances have allowed scientists
to study tumour complexity in more detail. Following
exome sequencing on multiple spatially separated
samples obtained from primary carcinomas and
metastatic sites, intratumour heterogeneity and parallel
evolution of subclonal driver events was uncovered
[4–7]. Multi-region sequencing has now been performed
in many cancer types including breast, lung, colorectal,
renal, oesophageal cancer and glioma, uncovering intratu-
mour heterogeneity in all cancer types studied [4–15].
Drivers of heterogeneity
Intratumoral heterogeneity exists in many forms, from
somatic coding and non-coding alterations to epigenetic,
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transcriptomic and post-translational modifications
[16, 17]. Intratumoral copy number heterogeneity also
exists (see [16]). Many endogenous triggers of cancer
genome instability contribute to intercellular hetero-
geneity (see [18]), some of which may be thera-
peutically exploitable. Defective DNA mismatch repair
results in hypermutation and microsatellite instability,
and mutations inhibiting the proofreading ability of
DNA polymerases δ and ε increase base mismatches
[19]. Evidence also exists that tumour cell dormancy
contributes to tumour heterogeneity (see [20]). Recently,
it has been uncovered that APOBEC (apolipoprotein B
mRNA editing enzyme catalytic polypeptide) family mem-
bers are endogenous drivers of tumour diversity in many
tumour types [21]. These enzymes initiate DNA cytosine
deamination [21, 22], and are a major source of subclonal
cancer gene mutations in bladder, breast, head and neck
squamous cancers, lung adenocarcinomas and lung squa-
mous cell carcinomas [21, 23–26]. External factors such
as cytotoxic therapy [27, 28], and patient factors such as
genetic background [29, 30], can also influence tumour
heterogeneity.
Mechanisms mediating levels of genomic
instability and tumour heterogeneity
Cahill and Vogelstein [31] discussed the conflict
between disadvantages and advantages of genomic
instability in tumour evolution. They questioned how
cancer cells are able to select for alterations driving
genomic instability, which is, usually disadvantageous
to the cell, can sometimes lead to cell death, and has
no direct growth advantage [31]. Looking to basic stud-
ies of mutation rate and cellular fitness in bacteria, the
authors reasoned that in stressful environments bac-
teria with higher overall levels of genomic instability
eventually dominate the population because they can
adapt [31]. This model can be applied to tumour popu-
lations, where genomic instability may be critical for
tumour progression [31].
Most normal diploid cells negatively select against
chromosomal instability (CIN). This is partially mediated
by p53, which inhibits cell propagation after genome
instability [32, 33]. CIN mouse models support the
concept that low or moderate CfIN levels promote
tumour formation, but excessive CIN suppresses tumour
formation [34]. This is analogous to mutational melt-
down and error-prone catastrophe in bacterial and viral
genetics [34–37]. Aneuploid, specifically trisomic cell
lines, grow poorly in vitro and as xenografts compared
to genetically matched euploid cells [38]. Yet, following
prolonged growth, aneuploid cells adapt by acquiring
additional alterations correlating with improved fitness
[38]. While aneuploidy was detrimental initially, over
time it became more advantageous.
In tumours, selection might favour the mitigation of
excessive CIN to prevent cell autonomous lethality.
Partial dysfunction of anaphase-promoting complex/
cyclosome (APC/C) lengthens mitosis, allowing more
time for correction of impending chromosome segrega-
tion errors. This permits tumour cells to fine-tune CIN
during tumour evolution, navigating the delicate equilib-
rium between cell death as a result of too much or too
little genomic instability [39]. In colorectal cancer, alter-
ations in BCL9L promote tolerance of chromosome mis-
segregation events, propagation of aneuploidy and
genetic heterogeneity [40]. This tolerance is induced
because BCL9L dysfunction leads to lower levels of
caspase-2, impairing MDM2 cleavage, p53 stabilisation,
and generation of the pro-apoptotic protein tBID, upon
chromosome missegregation [40].
Once cells have undergone genome doubling (GD),
propagation of aneuploidy follows as the tolerance of
GD allows cells to endure continuing CIN [41]. One
mechanism of GD tolerance involves cyclin D1, which
overrides a p53/p21-dependent checkpoint in G1, allow-
ing tetraploid cells to proliferate [42, 43]. Additional
mechanisms mediating levels of instability include
buffering protein changes caused by aneuploidy, activating
autophagy, and enhancing proteasomal degradation
[44, 45]. Mechanisms that both buffer and allow cells to
tolerate instability contribute to heterogeneity in tumours,
as cells that propagate genomic alterations and aneuploidy
survive. Understanding the processes that balance tumour
heterogeneity and promote aneuploidy tolerance may con-
tribute to novel therapeutics to prevent tumour hetero-
geneity and drug resistance.
Tumour heterogeneity and metastasis
The study of intratumour heterogeneity has yielded
novel findings about the timing and evolutionary drivers
of metastasis. Metastasis is a multistep process consist-
ing of local invasion, intravasation, survival in the circu-
lation, extravasation and distant colonisation [46, 47].
Two prominent models of metastasis are the linear
and parallel progression models [46–48]. Both are
founded on the clonal relationships between a primary
tumour and its metastases [47]. In the linear progression
model, metastasis is seeded at a late stage of tumour
progression, resulting in minimal genetic divergence be-
tween the primary tumour and its metastases [47]. Con-
versely, in the parallel progression model, metastases are
seeded early in tumour progression, so high levels of
genetic divergence are expected between the primary
tumour and its metastases [47, 49, 50] (Fig. 1). To
reconcile either model requires accounting for the
subclonal complexity of the primary tumour and its
relationship to subclones present at the metastatic sites
(see [47]).
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In colorectal, breast, pancreatic, renal, and prostate
cancer, multiregional sequencing supports both meta-
static models [47]. Both models were observed in one
colorectal cancer case [51]. One large metastasis had
genetically diverged from the primary tumour suggest-
ing early formation, while the other metastases were
similar to the primary tumour, so most likely dissemi-
nated at a late stage of tumour progression [51]. This
implies that heterogeneous subclones can form mul-
tiple distinct metastases. In breast and pancreatic can-
cer mouse models, metastases aligned with the parallel
progression model [50, 52–54], whereas the linear pro-
gression model was supported in a lung adenocarcin-
oma mouse model [48].
These data suggest metastasis is complex and diverse,
and that tumour heterogeneity is critical in the meta-
static process. Since more work is required to under-
stand tumour heterogeneity in late stage tumours and
metastases, in depth efforts are now examining post-
mortem tumour heterogeneity. The UK national PEACE
autopsy (posthumous evaluation of advanced cancer
environment) program, may help to decipher the
complexity cancer evolutionary processes at death.
Subclonal interactions in heterogeneous tumours
Background and Drosophila melanogaster models of
subclonal interaction
It was recognised in the 1970s that heterogeneous sub-
clones within tumours contain differing capacities for
growth and metastatic ability [55–57]. Early work also
recognised that interactions between subpopulations re-
sulted in differences in drug sensitivity when injected
into opposite flanks of mice or co-cultured in collagen
[58, 59]. The importance of these studies was not fully
recognised until over two decades later [60].
Growing interest in tumour heterogeneity and subclo-
nal interactions led to the development of a useful
model for studying subclonal competition and cooper-
ation in Drosophila melanogaster [60]. Eichenlaub et al.
[61] used a D. melanogaster model of epithelial tumour
formation to show that overexpression of both epider-
mal growth factor receptor (EGFR) and miR-8 in wing
imaginal disc cells results in supercompetitive cells that
engulf those surrounding them. These supercompetitive
cells drive tumourigenesis and metastasis, whereas cells
overexpressing either EGFR or miR-8 alone do not.
Competition between normal and oncogenic tissues was
also uncovered: in D. melanogaster, imaginal epithelial
cells activate nonapoptotic JNK signalling in response to
oncogenic mutant cells [62]. This leads to the activation
of the ELMO/Mbc-mediated phagocytic pathway, which
eliminates oncogenic cells [62]. Growing evidence sug-
gests that subclones within tumours compete, but also
cooperate. Several D. melanogaster studies demonstrated
cooperation between cells with oncogenic RasV12 mutations
and cells lacking the scribbled gene (scrib-/-) to promote
growth and invasion of the RasV12 mutant cells [60, 63].
Xenotransplant models of subclonal interaction
Xenotransplant models have been used to understand
interactions between human tumour subclones. In a
glioblastoma multiforme mouse xenotransplant model, a
minor mutant EGFR subpopulation enhanced tumouri-
genicity of the entire tumour. This occurred via a para-
crine mechanism that promoted growth in wtEGFR cells
within the tumour, illustrating the advantages of hetero-
geneity [64]. In a zebrafish-melanoma xenograft model,
inherently invasive (MITFhigh) melanoma cells coopera-
ted with poorly invasive (MITFlow) cells to invade away
from the primary site through solid tissue [65]. The pro-
tease activity and extracellular matrix deposition of
MITFhigh cells around the primary tumour was critical
for this co-invasion of MITFhigh and MITFlow cells [65].
Heterogeneity may be critical in tumour progression
and metastasis.
Polyak and colleagues [66] used a mouse xenograft
model to investigate the effect of a polyclonal tumour
population on tumour growth and metastasis. A minor
Fig. 1 The linear progression model versus the parallel progression
model of tumour evolution. In the linear progression model (upper panel),
late stage tumour cells disseminate and form metastases. In contrast,
in the parallel progression model (lower panel), early tumour cells
disseminate and form metastases alongside the primary tumour, and
both primary tumour and metastases progress in parallel gaining
multiple subclonal populations
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IL11-overexpressing subclone changed the tumour
microenvironment by increasing intratumoural vascular-
isation and reorganising extracellular matrix, in turn
increasing tumour growth [66]. Importantly, this sub-
clone was also outcompeted by a faster proliferating
competitor, leading to tumour collapse [66].
These xenograft studies provide insights into subclonal
interaction dynamics, demonstrating their complexity,
and that they are involved in many aspects of tumour
evolution including tumorigenesis, vascularisation, inva-
sion and metastasis.
Mouse models of subclonal interaction
Advances in molecular biology have allowed a deeper
study of subclonal cooperation in cancer mouse models.
Autochthonous models permit long-term study of clonal
dynamics in a specific genetic context [67].
In a mouse model of small cell lung cancer (SCLC),
tumours were composed of distinct cell populations with
either neuroendocrine or mesenchymal markers [68].
Both cell types shared specific genomic aberrations de-
rived from a common ancestor [68]. Transition between
the neuroendocrine and mesenchymal phenotype was
achieved through ectopic expression of RasV12, and the
mixed population endowed mesenchymal cells with
metastatic ability [68].
Cleary and colleagues [69] used a mouse model of breast
cancer to show that interclonal cooperation can be critical
for tumour propagation. A portion of tumours harboured
distinct HrasmutWntlow and luminal HraswtWnt1high sub-
clones, which cooperated to maintain tumour propagation
[69]. Although Wnt activation is rare in human breast can-
cer, this remains a valuable model for studying paracrine
mechanisms of subclonal communication.
In a p53-null mouse model of basal-like breast cancer,
two tumour cell populations were identified, one express-
ing mesenchymal markers (“mesenchymal-like” cells), and
another defined as tumour-initiating cells (TICs) [70].
When both populations were co-transplanted using
limited dilutions, mesenchymal-like cells promoted self-
renewal and tumour initiation capacity of the TICs [67].
Surprisingly, the mesenchymal population was maintained
as a minor subpopulation [70].
Mouse models have revealed how subpopulations
within tumours cooperate to promote tumour growth,
maintenance and metastasis. Although not fully re-
presentative of the clinical presentation of disease in
patients, these autochthonous models show the diverse
ways in which subclones can interact and affect tumour
progression. These studies suggest that to more
effectively treat heterogeneous tumours, we must first
understand the dynamics between different populations
within a tumour, and how targeted treatment changes
these interactions.
Therapy and subclonal resistance
Therapeutic resistance often develops in the advanced
setting following therapeutic targeting of clonal alter-
ations, as subclones containing somatic events driving
resistance can pre-exist or be generated de novo.
In non-small cell lung cancer (NSCLC) a low fre-
quency subclone with MET amplification was selected
for during treatment with EGFR tyrosine kinase inhibi-
tors (TKI), allowing for development of a resistant MET-
amplified tumour [71]. The EGFR T790M mutation,
which drives EGFR TKI resistance, was also present
prior to treatment in NSCLC [72]. In colorectal cancer,
EGFR antibody-resistant subclones with pre-existing
KRAS mutations emerged in 38% of patients following
5–6 months of treatment with panitumumab [73]. In pa-
tients with NSCLC, a subset of EGFR TKI resistant cancers
acquire alterations, such as RB and p53 loss contributing
to small cell carcinoma transformation [74].
In patients with HER2-positive breast cancer,
Janiszewska et al. [75] discovered a dramatic increase in
a minor resistant population of PIK3CA mutant cells,
and a slight decrease in the dominant population of
HER2-amplified cells post neoadjuvant therapy with tras-
tuzamab. Alterations in the phosphoinositide 3-kinase
(PI3K)-AKT pathway commonly drive resistance in
patients treated with the HER2-targeting antibody
trastuzamab [75].
In patients with colorectal cancer, mutant KRAS clones
emerging during treatment with EGFR-specific antibodies
declined during treatment breaks [76]. Engelman and
colleagues [77] demonstrated that resistance to EGFR
TKIs can develop through pre-existing clones and newly
developed drug-tolerant clones simultaneously, though
through separate mechanisms. When treating the NSCLC
cell line PC-9 with increasing concentrations of gefitinib,
one resistant population derived from EGFR T790M pre-
existing clones emerged early, while another with charac-
teristics of a drug-tolerant state and the EGFR T790M
mutation, emerged late. This late emergent EGFR T790M
subpopulation arose from drug-tolerant cells that were,
initially, partially resistant to gefitinib, and then gained the
EGFR T790 mutation to become fully resistant [77].
These studies demonstrate that heterogeneous tu-
mours develop resistance when specific clones are
targeted, allowing pre-existing or newly evolved sub-
clones to emerge.
Competition between subclones is frequently revealed
during and following therapy exposure. Keats and collabo-
rators [78] illustrated that, in a patient with multiple
myeloma, clonal dominance alternated between two main
subclones. Modelling these subclones in a mouse, treat-
ment with bortezomib exerted selective pressure on all
subclones, but one clone eventually emerged and outcom-
peted the others [78]. Conversely, minor therapy-resistant
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subpopulations can also support the survival of therapy-
sensitive populations, preserving tumour heterogeneity. In
patients with colorectal cancer, EGFR therapy-resistant
KRAS mutant subclones support non-mutant therapy-
sensitive cells by secreting increased levels of TGFalpha
and amphiregulin [79], in turn sustaining EGFR/ERK sig-
nalling in sensitive cells [79]. These data demonstrate how
resistance to targeted therapy can develop with both pres-
ervation and loss of heterogeneity.
Heterogeneity and patient outcome
Is intratumour heterogeneity associated with worse pa-
tient outcomes? In premalignant Barrett’s oesophagus,
clonal diversity is an important predictor of tumour
progression [80]. By adapting diversity measures from
ecology to measure both the number and abundance of
clones relative to others in the population, the upper
quartile of the number of clones and the genetic diver-
gence based on loss of heterozygosity (LOH) were
strongly predictive of increased progression from Barrett’s
oesophagus to oesophageal adenocarcinoma [80].
In breast, ovarian, gastric and NSCLC, there is a para-
doxical relationship between CIN and prognosis. The
worst outcomes are in tumours with intermediate CIN,
while those with extreme CIN scores had an improved
outcome [81, 82]. The tumour cell of origin and the
order of somatic events may also influence tumour het-
erogeneity and patient outcome [83].
In a recent study of 12 different cancer types [84],
mortality risk increased when more than two clones
coexisted in the same tumour sample, but decreased
with the coexistence of more than four clones, empha-
sising that heterogeneity levels within tumours can
strongly influence outcome [84]. Tumours with high
levels of somatic copy number alterations (SCNAs) have
increased proliferation markers and a decreased immune
signature [85]. Interestingly, both phenotypes are
controlled by different types of aneuploidy, and may be
important patient outcome markers, as patients with
higher SCNA levels tend to have worse responses to
immunotherapy [85]. Recently, our group demonstrated
in the TRACERx prospective study of 100 patients with
NSCLC, that heterogeneity of DNA copy number events
rather than point mutations, was associated with poor
outcome [86].
In breast cancer, enriched areas of tandem duplica-
tions previously thought to be unimportant passengers,
were shown to be potentially important for tumourigen-
esis [87]. These tandem duplications were characterised
into two different rearrangement signatures [87]: one
enriched in areas that disrupted tumour suppressor
genes such as PTEN and RB1, and the other enriched in
oncogenes, including MYC, and in putative regulatory
elements of genes such as ESR1, with direct effects on
transcription [87]. These enrichments demonstrate that
mutational processes not only stochastically mutate the
genome and induce heterogeneity but are also likely to
be critical in cancer evolution and patient outcome.
Further work to understand how established clinical
parameters of outcome such as tumour size, grade and
stage reflect intratumour heterogeneity is required.
Heterogeneity and immune responses in cancer
Emerging evidence suggests that intratumour heterogen-
eity may also influence the anti-tumour immune re-
sponse. Rapid advances in cancer genome sequencing
have enabled scientists to decipher the impact of somatic
coding alterations upon immune recognition and sur-
veillance. Non-silent mutations generate neoantigens
that can be recognised by the immune system [88, 89].
Both CD4+ and CD8+ T lymphocytes were shown to
recognise tumour neoantigens [89–93]. Using whole
genome sequencing, scientists have established that
mutation burden is highly variable among different
tumour types [94]. Mutation levels in melanomas and
lung cancers are among the highest because of exposure
to ultraviolet light and tobacco carcinogens respectively
[94, 95]. This makes these cancer types ideal candidates
for immunotherapy; however, others such as clear cell
renal cancer also respond to checkpoint therapy despite
a much lower mutational burden [96].
Mutation burden and immunotherapy
In patients with melanoma, whole exomes from pre-
treatment melanoma tumour biopsies and matching germ-
line tissue samples were examined to determine if neoanti-
gen burden affects responses to antibodies directed against
cytotoxic T lymphocyte-associated antigen-4 (CTLA4)
[97]. Overall mutational load and expression of cytolytic
markers in the immune microenvironment were signifi-
cantly associated with an anti-CTLA4 response and clinical
benefit [97].
Rizvi and colleagues [98] explored how mutational
burden affects sensitivity to PD-1 blockade in NSCLC.
Expressed by activated T cells, PD-1 is a key immune
checkpoint receptor that mediates immunosuppression
[88]. They concluded that a higher nonsynonymous mu-
tation burden was associated with improved objective
response, durable clinical benefit and progression-free
survival [98]. However, some patients with both high
and low mutational burdens failed to respond to therapy
[98], suggesting that other factors are involved in im-
munotherapy responses.
We investigated whether melanoma and NSCLC sensi-
tivity to PD-1 and CTLA-4 treatment was enhanced in
tumours where tumours had a high clonal neoantigen
burden. Considering a combination of neoantigen
clonality and neoantigen burden allowed us to better
Caswell and Swanton BMC Medicine  (2017) 15:133 Page 5 of 9
discriminate responder from non-responder patients
than either metric alone [99]. These findings suggest
that the degree of intratumour heterogeneity may be
associated with a differential response to checkpoint
blockade, and that multiple factors are involved in
tumour immune responses. These studies raise the
possibility that technologies now exist to exploit
clonal neoantigens, present in every tumour cell for
therapeutic benefit, either through vaccination or cell
therapy approaches.
Resistance and immune evasion
Multiple laboratories are now focusing on a deeper
understanding of immune evasion and resistance to
immunotherapy. One study [100] uncovered two
novel mechanisms of evasion: first, the elimination of
neoantigen-containing tumour cells within a subset of
the tumour population, and second, the acquisition of one
or more genetic events that resulted in neoantigen loss.
Both clonal and subclonal alterations were lost following
immunotherapy, but all clonal neoantigens were elimi-
nated by chromosomal deletions and LOH, whereas
subclonal neoantigens were lost through LOH and elimin-
ation of tumour cells [100]. We uncovered that CIN likely
contributes to mutational heterogeneity within tumours
through SCNAs [86]. More than 14% of subclonal muta-
tions (range: 0–56%) are subclonal because of SCNA loss
events of clonal alterations [86]. This suggests that CIN
contributes to neoantigen heterogeneity, and may play a
role in immune evasion and immunotherapy resistance.
These findings raise questions about whether immuno-
therapy will be effective as tumours evolve and become
heterogeneous, and to what extent underlying CIN,
resulting in rapid karyotype evolution, drives resistance
to such approaches. Understanding neoantigen hetero-
geneity within tumours will aid the development of
more effective, patient-specific immunotherapies, which
may not prevent eventual relapse but could significantly
extend patient’s lives.
T cell exhaustion is another mechanism of immune
evasion. This state of T cell dysfunction arises during
chronic antigen exposure, which is defined by poor
effector function, sustained expression of inhibitory
receptors, and an abnormal transcriptional state [101–103].
In this state, PD-1 is one of many cell surface inhibitory re-
ceptors to co-regulate T cell exhaustion [103]. Anti-PD-1
immunotherapy partially restores T cell function from an
exhausted state [102, 104, 105]. It is also clear that the
relative abundance of partially exhausted tumour-
infiltrating CD8+ T cells predicts response to anti-PD-1
therapy [106]. However, resistance to PD-1 therapy
develops in many patients.
Alterations in the genes encoding interferon receptor-
associated Janus kinase 1 (JAK1) or 2 (JAK2), along with
deletion of the wild-type allele, lead to defects in path-
ways involved in interferon receptor signalling and in
antigen presentation. This results in resistance to PD-1
blockade in melanoma [107]. Loss of PTEN also inhibits
T cell-mediated tumour-killing by decreasing T cell infil-
tration in tumours, and is associated with worse out-
comes with anti PD-1 therapy [108]. These studies
suggest that tumour heterogeneity is beneficial to im-
mune evasion and the development of immunotherapy
resistance. Approaches that attenuate tumour heterogen-
eity by inhibiting the molecular mechanisms driving
cell-to-cell variation, or that target multiple truncal
mutations occurring consistently in all regions of the
tumour while stimulating the immune response using
checkpoint blockade, might help limit diversity and re-
sistance acquisition [99].
Conclusions
We have begun to witness how tumour heterogeneity
affects tumour progression and metastasis, and the
tumour immune response. A deeper understanding of
how the immune system can be leveraged to tackle
clonal alterations within tumour cells is required, to
identify high-risk tumour subclones that might be extin-
guished prior to, or at the time of, metastatic seeding.
Longitudinal characterisation of tumour evolution using
advanced sequencing technology is important, as will be
characterisation of the distinct mechanisms of tumour
heterogeneity from tumour diagnosis through to pro-
gression and death. These studies may open avenues to
attenuate tumour heterogeneity in minimal residual dis-
ease when disease burden is low, or to target multiple
clonal mutations present in every cell simultaneously to
limit the acquisition of therapy resistance.
As tumour heterogeneity is arguably the major force
behind tumour progression, evolution and metastasis,
insight into the clonal complexity of individual tumours
and its contribution to progression, immune evasion and
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